An aldose reductase inhibitor that blocks the conversion of glucose to sorbitol (Kis = 7.7 nM and 60 μM, for aldose reductase 2 and 1, respectively); prevents diabetes-induced alterations of the cardiovascular system in 14-day streptozotocin-diabetic rats; impairs the synthesis of PGF2α by human cultured preadipocytes.